de Reijke TM - Search Results

1

Intermittent androgen deprivation in advanced prostate cancer.

de Reijke TM. de Reijke TM. Urol Res. 1997;25 Suppl 2:S63-6. doi: 10.1007/BF00941990. Urol Res. 1997. PMID: 9144889 Review. No abstract available.

2

Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.

Kil PJ, Goldschmidt HM, Wieggers BJ, Kariakine OB, Studer UE, Whelan P, Hetherington J, de Reijke TM, Hoekstra JW, Collette L. Kil PJ, et al. Among authors: de reijke tm. Eur Urol. 2003 Jan;43(1):31-8. doi: 10.1016/s0302-2838(02)00499-2. Eur Urol. 2003. PMID: 12507541

3

[Practice guideline 'Prostate cancer: diagnosis and treatment'].

de Reijke TM, Battermann JJ, van Moorselaar RJ, de Jong IJ, Visser AP, Burgers JS. de Reijke TM, et al. Among authors: de jong ij. Ned Tijdschr Geneeskd. 2008 Aug 9;152(32):1771-5. Ned Tijdschr Geneeskd. 2008. PMID: 18754308 Review. Dutch.

4

Long-term complications of brachytherapy in local prostate cancer.

de Reijke TM, Laguna MP. de Reijke TM, et al. BJU Int. 2003 Nov;92(8):869-73. doi: 10.1046/j.1464-410x.2003.04497.x. BJU Int. 2003. PMID: 14616437 Review. No abstract available.

5

New developments in castrate-resistant prostate cancer.

Shore N, Mason M, de Reijke TM. Shore N, et al. Among authors: de reijke tm. BJU Int. 2012 Jun;109 Suppl 6:22-32. doi: 10.1111/j.1464-410X.2012.11217.x. BJU Int. 2012. PMID: 22672122 Review.

6

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark N, Debois M, Collette L. Oosterhof GO, et al. Among authors: de reijke tm. Eur Urol. 2003 Nov;44(5):519-26. doi: 10.1016/s0302-2838(03)00364-6. Eur Urol. 2003. PMID: 14572748 Clinical Trial.

7

Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement.

de Reijke TM, Klarskov P. de Reijke TM, et al. BJU Int. 2004 Apr;93(6):757-62. doi: 10.1111/j.1464-410X.2003.04720.x. BJU Int. 2004. PMID: 15049986 Clinical Trial.

8

Controversies in the management of T1 urothelial bladder cancer.

Azzouz H, Cauberg EC, De Reijke TM. Azzouz H, et al. Among authors: de reijke tm. Minerva Urol Nefrol. 2011 Dec;63(4):309-15. Minerva Urol Nefrol. 2011. PMID: 21996986 Review.

9

Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.

Bolla M, de Reijke TM, Zurlo A, Collette L. Bolla M, et al. Among authors: de reijke tm. Front Radiat Ther Oncol. 2002;36:81-6. doi: 10.1159/000061332. Front Radiat Ther Oncol. 2002. PMID: 11842758 No abstract available.

10

[Providing patients with an audio recording of the outpatient oncological consultation; experiences of patients and physicians].

Ong LM, de Haes JC, Kruyver IP, de Reijke TM, Lammes FB. Ong LM, et al. Among authors: de reijke tm, de haes jc. Ned Tijdschr Geneeskd. 1995 Jan 14;139(2):77-80. Ned Tijdschr Geneeskd. 1995. PMID: 7838223 Dutch.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

239 results

Search Page

Filters